Dalfampridine Dosage
This dosage information may not include all the information needed to use Dalfampridine safely and effectively. See additional information for Dalfampridine.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Usual Geriatric Dose for:
Additional dosage information:
Usual Adult Dose for Multiple Sclerosis
Maximum recommended dose: 10 mg every 12 hours, taken with or without food
Patients should not take double or extra doses if a dose is missed.
Tablets should only be taken whole. Tablets should not be divided, crushed, chewed, or dissolved.
Usual Geriatric Dose for Multiple Sclerosis
Maximum recommended dose: 10 mg every 12 hours, taken with or without food
Patients should not take double or extra doses if a dose is missed.
Tablets should only be taken whole. Tablets should not be divided, crushed, chewed, or dissolved.
A population pharmacokinetic analysis showed that dalfampridine clearance modestly decreased with increasing age, but not sufficiently to necessitate a modification of dose.
Renal Dose Adjustments
Dalfampridine is contraindicated in patients with moderate or severe renal impairment (CrCl less than or equal to 50 mL/min). The risk of seizures in patients with mild renal impairment (CrCl 51 to 80 mL/min) is unknown, but dalfampridine plasma levels in these patients may approach those seen at a dose of 15 mg twice daily, a dose that may be associated with an increased risk of seizures.
Liver Dose Adjustments
The pharmacokinetics of dalfampridine in hepatically impaired subjects has not been studied. Since dalfampridine is primarily excreted unchanged in the urine, hepatic impairment is not expected to significantly affect dalfampridine pharmacokinetics or recommended dosing.
Dose Adjustments
A population pharmacokinetic analysis suggested that female patients would be expected to have higher maximum dalfampridine plasma concentration than male patients. The magnitude of these differences is small and does not necessitate any dose modification.
Precautions
Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).
Dialysis
Data not available
Other Comments
The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for dalfampridine. It includes a Medication Guide and communication plan. Additional information is available at www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm.
